Vittorina Zagonel
#152,618
Most Influential Person Now
Researcher
Vittorina Zagonel's AcademicInfluence.com Rankings
Vittorina Zagonelcomputer-science Degrees
Computer Science
#8138
World Rank
#8560
Historical Rank
Machine Learning
#3242
World Rank
#3281
Historical Rank
Artificial Intelligence
#3549
World Rank
#3599
Historical Rank
Database
#5170
World Rank
#5370
Historical Rank
Download Badge
Computer Science
Vittorina Zagonel's Degrees
- PhD Computer Science University of Milan
- Masters Computer Engineering University of Padua
- Bachelors Information Technology University of Bologna
Similar Degrees You Can Earn
Why Is Vittorina Zagonel Influential?
(Suggest an Edit or Addition)Vittorina Zagonel's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. (2018) (1462)
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma (2018) (1362)
- Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. (2002) (821)
- Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. (2014) (798)
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. (2016) (639)
- ALK+ lymphoma: clinico-pathological findings and outcome. (1999) (572)
- Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. (2002) (305)
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. (2018) (249)
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma (2018) (237)
- CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. (1998) (233)
- Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. (1997) (220)
- Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. (2000) (219)
- Kaposi's sarcoma‐associated herpesvirus DNA sequences in AIDS‐related and AIDS‐unrelated lymphomatous effusions (1996) (206)
- Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study (2017) (205)
- Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. (1995) (200)
- Assessment of a HER2 scoring system for colorectal cancer: results from a validation study (2015) (199)
- Validation of a multidimensional evaluation scale for use in elderly cancer patients (1996) (189)
- Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. (2015) (185)
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. (2014) (181)
- Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. (2002) (167)
- Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. (2019) (166)
- Gender medicine: a task for the third millennium (2013) (165)
- Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. (2001) (154)
- 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. (1993) (136)
- Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. (2020) (135)
- BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection (2015) (134)
- Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. (1996) (131)
- Hepatitis C virus and non‐Hodgkin's lymphomas (1996) (130)
- Fludarabine, cytarabine, and G‐CSF (FLAG) for the treatment of poor risk acute myeloid leukemia (1998) (124)
- Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. (2016) (118)
- CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. (1997) (115)
- Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. (2016) (110)
- Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. (2002) (109)
- Nutritional Support in Cancer Patients: A Position Paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE) (2016) (107)
- Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer (2017) (105)
- Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. (2018) (104)
- Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study. (1988) (104)
- Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. (1990) (103)
- Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. (1998) (102)
- The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. (2013) (99)
- The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. (1995) (97)
- Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. (1994) (97)
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (2020) (95)
- Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. (2016) (94)
- Epidemiology and Pattern of Care of Breakthrough Cancer Pain in a Longitudinal Sample of Cancer Patients: Results From the Cancer Pain Outcome Research Study Group (2011) (92)
- 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. (1993) (90)
- A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. (1992) (88)
- FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). (2013) (88)
- Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. (1993) (83)
- Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. (1994) (82)
- Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. (2015) (82)
- 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? (2003) (81)
- Burkitt's lymphoma in adults with and without human immunodeficiency virus infection (1998) (81)
- FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. (2013) (80)
- CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. (1996) (77)
- Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). (2005) (76)
- Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial (2018) (74)
- Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial (2018) (74)
- Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. (2017) (73)
- Lung cancer in the elderly. (1997) (71)
- Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer (2014) (70)
- Age as a risk factor for inadequate treatment. (1988) (70)
- HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. (2019) (70)
- Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. (2011) (69)
- Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives (2020) (69)
- Immunotherapy in Gastrointestinal Cancers (2017) (69)
- Hepatitis C virus, non-Hodgkin's lymphomas and hepatocellular carcinoma (1998) (68)
- Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia. (1991) (68)
- CD30 (Ki-1)-positive anaplastic large-cell lymphomas in 13 patients with and 27 patients without human immunodeficiency virus infection: the first comparative clinicopathologic study from a single institution that also includes 80 patients with other human immunodeficiency virus-related systemic lym (1995) (68)
- Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial (2020) (68)
- Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. (2020) (67)
- Head and neck cancer and ageing: a retrospective study in 438 patients (1990) (67)
- Prevalence of functional disability among elderly patients with cancer. (2001) (66)
- Acute myeloid leukemia in the elderly: biology and therapeutic strategies. (2001) (65)
- Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives (2019) (64)
- Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. (2000) (64)
- Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer (2013) (63)
- A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. (2008) (63)
- Early HER2 dysregulation in gastric and oesophageal carcinogenesis (2012) (63)
- Awareness and consideration of malnutrition among oncologists: Insights from an exploratory survey. (2016) (62)
- 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. (1989) (61)
- Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. (2015) (60)
- PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review. (2019) (59)
- AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. (2016) (58)
- Expert conference on cancer pain assessment and classification—the need for international consensus: working proposals on international standards (2011) (57)
- High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. (1985) (57)
- FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. (2018) (56)
- The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. (2013) (55)
- Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center (2015) (55)
- Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. (2019) (55)
- Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma (2018) (55)
- Expression of the RET receptor tyrosine kinase and GDNFR-alpha in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. (1997) (54)
- Non-Hodgkin's lymphomas in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients. (1987) (52)
- Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study (2015) (50)
- Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization (2019) (48)
- Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment (2013) (48)
- Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients (2016) (47)
- Non‐Hodgkin's lymphoma in the elderly I. Pathologic features at presentation (1990) (46)
- Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the Art (2016) (46)
- Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. (2015) (46)
- The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. (2013) (45)
- Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients (2017) (45)
- Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. (2020) (45)
- Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO (2018) (44)
- A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. (2019) (44)
- Commission of the European Communities "Europe Against Cancer" Programme. European school of oncology advisory report. Cancer treatment in the elderly. (1993) (44)
- Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. (1997) (43)
- HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. (2015) (43)
- Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer. (2018) (43)
- Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. (2014) (42)
- Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. (1998) (41)
- Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. (2020) (41)
- Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab (2014) (41)
- The role of tumor angiogenesis as a therapeutic target in colorectal cancer (2018) (40)
- Parenteral nutrition in cancer patients receiving chemotherapy: effects on toxicity and nutritional status. (1993) (40)
- Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1 (1997) (40)
- Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. (2011) (40)
- Nutritional support for cancer patients: still a neglected right? (2017) (40)
- Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial. (2017) (40)
- Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. (2014) (40)
- The impact of cancer on the physical function of the elderly and their utilization of health care (1998) (39)
- Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology) (2015) (39)
- Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study. (2013) (38)
- Immune senescence and cancer in elderly patients: Results from an exploratory study (2013) (38)
- A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib. (2020) (37)
- Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa) (2014) (37)
- Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy (2014) (37)
- Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients (2014) (37)
- FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. (2013) (37)
- Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. (2011) (37)
- Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study (2020) (36)
- Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer (2012) (36)
- Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk (2018) (35)
- Pros-IT CNR: an Italian prostate cancer monitoring project (2017) (35)
- On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2 (2020) (34)
- Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases (2021) (34)
- KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. (2018) (33)
- Fludarabine, cytarabine, and granulocyte‐colony stimulating factor for the treatment of high risk myelodysplastic syndromes (1999) (33)
- Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study (2018) (33)
- A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group (2007) (33)
- Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial. (2005) (33)
- ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. (2017) (33)
- Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer. (2016) (33)
- Clinical Management of Diffuse Low-Grade Gliomas (2020) (32)
- Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature (2013) (32)
- The Role of Laparoscopy in Peritoneal Surface Malignancies Selected for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (2012) (32)
- Non‐Hodgkin's lymphoma in the elderly. A retrospective clinicopathologic study of 50 patients (1986) (31)
- A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. (2018) (31)
- Differential expression of cell adhesion molecules in b‐zone small lymphocytic lymphoma and other well‐differentiated lymphocytic disorders (1993) (31)
- Hepatoid Adenocarcinoma of the Colon: What Should We Target? (2011) (30)
- Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3',5'-cyclic monophosphate. (1992) (30)
- Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma (2002) (29)
- Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. (2017) (29)
- In vitro and in vivo effects of 2′‐deoxycoformycin (Pentostatin) on tumour cells from human γδ+ T‐cell malignancies (2000) (29)
- Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. (2016) (28)
- Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. (2019) (28)
- Monocytoid B-cell lymphoma with bone marrow and peripheral blood involvement at presentation. (1989) (28)
- B-zone small lymphocytic lymphoma: a morphologic, immunophenotypic, and clinical study with comparison to "well-differentiated" lymphocytic disorders. (1992) (28)
- Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update. (2020) (28)
- Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer. (1988) (28)
- Ultrasound assessment of oxaliplatin‐induced neuropathy and correlations with neurophysiologic findings (2013) (27)
- Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients. (1994) (27)
- The Combination of Gemcitabine and Vinorelbine is an Active Regimen as Second-Line Therapy in Patients with Metastatic Breast Cancer Pretreated with Taxanes and/or Anthracyclines: a Phase I–II Study (2003) (26)
- The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. (2021) (26)
- TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group (2017) (26)
- HER2 amplification as a ‘molecular bait’ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial. (2016) (25)
- Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of (2017) (25)
- Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. (2020) (24)
- 5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. (1994) (24)
- First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response (2015) (24)
- First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (2018) (24)
- EXPRESSION OF NATURAL KILLER ANTIGENS IN A SUBSET OF “ON‐T. NON‐B LYMPHOMA/LEUKAEMIA WITH HISTIOCYTIC FEATURES” (1990) (24)
- Combination chemotherapy specifically devised for elderly patients with unfavorable non-Hodgkin's lymphoma. (1990) (24)
- CD13 Expression in B-Cell Chronic Lymphocytic Leukemia is Associated with the Pattern of Bone Marrow Infiltration (1992) (23)
- First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study. (2020) (23)
- Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes (2018) (23)
- Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy. (2012) (23)
- High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib (2019) (23)
- A Phase II Study of Oral Idarubicin (4‐Demethoxidaunorubicin) in Previously Untreated Elderly Patients with Non‐Hodgkin's Lymphoma (1991) (23)
- Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC). (2018) (23)
- Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives (2017) (23)
- Targeted approaches to triple-negative breast cancer: current practice and future directions. (2013) (22)
- DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (2017) (22)
- Hodgkin’s disease: A disorder of dysregulated cellular cross-talk (1998) (21)
- Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. (2019) (21)
- Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. (2015) (21)
- Expression of Epstein-Barr virus-encoded latent membrane protein 1 in nonendemic Burkitt's lymphomas. (1996) (21)
- Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. (2015) (21)
- Treatment of Malignant Gliomas in Elderly Patients: A Concise Overview of the Literature (2014) (21)
- The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up‐regulated upon differentiation (1999) (21)
- Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. (2017) (20)
- Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy. (2020) (20)
- Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma (2021) (20)
- Radiomics predicts response of individual HER2‐amplified colorectal cancer liver metastases in patients treated with HER2‐targeted therapy (2020) (20)
- Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer (2017) (20)
- Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial. (2015) (19)
- Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non‐Hodgkin's lymphomas. A 9‐year experience at a single institution (1994) (19)
- Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression. (2020) (19)
- Immunotherapy and urothelial carcinoma: An overview and future prospectives. (2019) (19)
- Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study (2021) (19)
- Follicular lymphoma of compartmentalized small cleaved center cells and mantle zone lymphocytes. Evidence for a common derivation. (1992) (19)
- Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care) (2017) (18)
- Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results (2015) (18)
- A new informed consent form model for cancer patients: preliminary results of a prospective study by the Italian Association of Medical Oncology (AIOM). (2012) (18)
- Conventional brain MRI features distinguishing limbic encephalitis from mesial temporal glioma (2019) (18)
- Intermediate lymphocytic lymphoma encompassing diffuse and mantle zone pattern variants. A distinct entity among low-grade lymphomas? (1989) (18)
- Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis (2012) (18)
- Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy. (1994) (18)
- Lymphoma : Clinico-Pathological Findings and Outcome (1999) (18)
- Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. (2016) (17)
- Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up (2016) (17)
- Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years). (2013) (17)
- CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer (2019) (17)
- Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status (2019) (17)
- Importance of a comprehensive geriatric assessment in older cancer patients. (2001) (17)
- Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study (2021) (17)
- The Medical Oncologist's Role in Palliative Care: AIOM's Position (2009) (17)
- Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series. (2013) (17)
- Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial (2019) (17)
- Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis (2020) (17)
- Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A “real-life” study. (2015) (16)
- Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC). (2020) (16)
- Reducing chemotherapy-associated toxicity in elderly cancer patients. (1996) (16)
- In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients. (1993) (15)
- Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients (2019) (15)
- The Aged Patient with Lung Cancer (1994) (15)
- Differential expression of the RET gene in human acute myeloid leukemia (1998) (15)
- Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey (2016) (15)
- Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. (2016) (15)
- Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas (2021) (15)
- Treatment of non‐Hodgkin's lymphoma in the elderly: an update (1998) (15)
- Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer (2016) (14)
- Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma (2011) (14)
- Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma (2018) (14)
- Carcinoembryonic Antigen (CEA) in the Follow-Up of Disease-Free Breast Cancer Patients (1982) (14)
- Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors (2021) (14)
- Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. (2019) (14)
- Immune senescence and immune activation in elderly colorectal cancer patients (2019) (14)
- Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study (2021) (13)
- Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. (2015) (13)
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma (2018) (13)
- FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group. (2015) (13)
- Cisplatin and Temozolomide Combination in the Treatment of Supratentorial Anaplastic Ependymoma (2013) (13)
- FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial (2016) (13)
- 402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment (2020) (13)
- Older cancer patients and COVID‐19 outbreak: Practical considerations and recommendations (2020) (13)
- Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) (2020) (13)
- Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol (2018) (13)
- Induction of LFA-1/CD11a and ICAM-1/CD54 adhesion molecules on neoplastic B cells during in vivo treatment of chronic lymphocytic leukemia with interferon-alpha 2. (1993) (13)
- Prevalence of pain in patients with cancer aged 70 years or older: A prospective observational study. (2019) (13)
- Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome. (2010) (12)
- Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study (2020) (12)
- Extraskeletal Myxoid Chondrosarcoma: Clinical and Molecular Characteristics and Outcomes of Patients Treated at Two Institutions (2020) (12)
- Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib (2020) (12)
- Prognostic Role of Circulating Tumor Cells (CTCS) in Metastatic Renal Cell Carcinoma: A Large, Multicenter Prospective Trial. (2017) (12)
- D01*Final Results of the HERACLES trial in HER2 amplified colorectal cancer (2016) (12)
- Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. (2020) (12)
- Prognostic value of multidimensional geriatric assessment (MGA) on survival of a prospective cohort of 880 elderly cancer patients (ECP). (2011) (12)
- The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients (2018) (12)
- Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration‐resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region (2019) (12)
- Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. (2022) (12)
- Induction of LFA-1/CD11a and ICAM-1/CD54 adhesion molecules on neoplastic B cells during in vivo treatment of chronic lymphocytic leukemia with interferon-alpha 2 [letter; comment] (1993) (12)
- PET/CT imaging in gynecologic malignancies: a critical overview of its clinical impact and our retrospective single center analysis. (2012) (12)
- Changes in food habits in cancer patients in Italy: a survey. AIOM - SINPE - FAVO. (2018) (12)
- 414ORANDOMIZED PHASE II TRIAL AVAREG (ML25739) WITH BEVACIZUMAB (BEV) OR FOTEMUSTINE (FTM) IN RECURRENT GBM: FINAL RESULTS FROM THE RANDOMIZED PHASE II TRIAL. (2014) (11)
- Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update. (2021) (11)
- Induction of Both CD8+ and CD4+ T-Cell–Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1 (2008) (11)
- Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma. (2012) (11)
- Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study (2020) (11)
- Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. (2020) (11)
- The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. (2019) (11)
- Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas. (2013) (11)
- Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO. (2016) (11)
- In vitro and in vivo effects of 2'-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies. (2000) (11)
- First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial (2017) (11)
- The Path of Cicely Saunders: The “Peculiar Beauty” of Palliative Care (2020) (11)
- Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study (2018) (11)
- Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study (2020) (11)
- Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study (2018) (11)
- Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. (2019) (11)
- Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification). (2013) (11)
- Discordance of IDH mutational status between lesions in an adult patient with multifocal glioma. (2018) (10)
- Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study (2016) (10)
- Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial (2022) (10)
- Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update. (2018) (10)
- Expression of natural killer (NK) antigens in malignant histiocytosis and a subset of acute myelomonocytic leukaemias. (1989) (10)
- Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network: The ROVID Study (2021) (10)
- CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation. (1999) (10)
- An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab (2014) (10)
- Type 2 Epstein-Barr virus genome and latent membrane protein-1 expression in a T-cell-rich lymphoma of probable B-cell lineage. (1993) (10)
- A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial (2009) (10)
- Efficacy of Sym 004 in PatientsWithMetastatic Colorectal CancerWith Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNAAnalyses A Phase 2 Randomized Clinical Trial (2018) (10)
- Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study (2021) (10)
- Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma (2017) (10)
- A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma? (2020) (10)
- Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC). (2014) (10)
- Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience. (2016) (10)
- Consensus document of the Italian Association of Medical Oncology and the Italian Society of Palliative Care on early palliative care (2018) (9)
- Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy (2019) (9)
- EXPRESSION OF MYELOID ASSOCIATED ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (1992) (9)
- Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (2020) (9)
- Report of an unusual small lymphocytic B‐cell lymphoma selectively involving the B‐zone of lymph node (1990) (9)
- O-0026FOLFOXIRI/BEVACIZUMAB VERSUS FOLFIRI/BEVACIZUMAB AS FIRST-LINE TREATMENT IN UNRESECTABLE METASTATIC COLORECTAL CANCER: RESULTS OF PHASE III TRIBE TRIAL BY GONO GROUP (2013) (9)
- Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. (2016) (9)
- Gastroduodenal involvement in staging of nodal non-Hodgkin lymphomas: a clinical and endoscopic prospective study of 235 patients. (1995) (9)
- Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. (2020) (9)
- Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study. (2012) (9)
- Clinical Characteristics, Diagnosis and Treatment of Elderly Patients with Lung Cancer at Non-Surgical Institutions: A Multicenter Study (1990) (8)
- Bone marrow involvement in cutaneous T-cell lymphoma. (1990) (8)
- Immune checkpoint inhibitors rechallenge in urological tumors: an extensive review of the literature (2022) (8)
- Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study (2020) (8)
- Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study). (2020) (8)
- Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study. (2021) (8)
- Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience (2015) (8)
- Hepatitis C virus and non-Hodgkins lymphoma (1996) (8)
- Letter to Editor: Reply to R.T. Casey (Semin Oncol. 2018 Jun;45(3):151-155). (2019) (8)
- Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system (2021) (8)
- Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study. (2013) (8)
- Phase II study of teniposide (VM‐26) in multiple myeloma (1985) (8)
- Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. (2017) (7)
- Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. (2021) (7)
- Caring for Patients with Advanced Stage Cancer at the Time of COVID‐19 (2020) (7)
- From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy (2020) (7)
- Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy (2018) (7)
- Abstract 2603: Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab + ipilimumab in CheckMate-142 (2018) (7)
- Nutritional Support in Cancer patients: update of the Italian Intersociety Working Group practical recommendations (2022) (7)
- Anaplastic Astrocytoma: State of the art and future directions. (2020) (7)
- GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH) (2019) (7)
- Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). (2021) (7)
- Efficacy and safety of radiotherapy (RT) plus temozolomide (TMZ) in elderly patients (EP) with glioblastoma (GBM). (2013) (7)
- Abstract A089: Exploiting clonal evolution and liquid biopsy to overcome resistance to anti-EGFR treatment in metastatic colorectal cancer: the CHRONOS trial (2018) (7)
- Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA Phase 3 Randomized Trial. (2020) (7)
- Analysis of clinical features of ovarian cancer (OC) and breast cancer (BC) among BRCA-mutated (BRCA+) and sporadic (NH) double tumors. (2012) (7)
- Staging and treatment with cyclophosphamide, vincristine and prednisone (CVP) in advanced cutaneous t‐cell lymphomas (1986) (7)
- Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study (2015) (7)
- Rarity of microsatellite genomic instability in B‐cell non‐Hodgkin's lymphomas in hepatitis C virus‐infected patients (1997) (7)
- Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas (2021) (6)
- Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. (2022) (6)
- Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. (2021) (6)
- An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer (2019) (6)
- FOLFOX4/XELOX in stage II–III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial. (2017) (6)
- PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction (2021) (6)
- Non-Hodgkin's Lymphoma in the Elderly: A Retrospective Evaluation of Toxicity Related to Aggressive vs. Conservative Treatments (1988) (6)
- Therapeutic choice with regard to life expectancy and cost benefit analysis in cancer diagnosis and treatment. (1998) (6)
- Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients (2018) (6)
- Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor (2019) (6)
- Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature. (2012) (6)
- A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab. (2015) (6)
- Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study) (2019) (6)
- cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma (2004) (5)
- Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO (2019) (5)
- Serum levels of adhesion molecules in haematopoietic tumours. (1994) (5)
- Periostin and Epithelial–Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma (2020) (5)
- Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14) (2021) (5)
- 2335 Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab-P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts) (2015) (5)
- Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment. (2015) (5)
- Comparison between 18f-Dopa and 18f-Fet Pet/Ct in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and our Experience. (2019) (5)
- Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2) (2019) (5)
- Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis (2021) (5)
- Human granulocyte-macrophage colony-stimulating factor supports the clonogenic growth of B-lineage acute lymphoblastic leukemias expressing myeloid antigens. (1997) (5)
- Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study. (2021) (5)
- Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients (2019) (5)
- AT-11FINAL RESULTS FROM THE RANDOMIZED PHASE II TRIAL AVAREG (ML25739) WITH BEVACIZUMAB (BEV) OR FOTEMUSTINE (FTM) IN RECURRENT GBM (2014) (5)
- Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural-economic status, awareness of disease and the relation with the oncologist. (2016) (5)
- REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS). (2017) (5)
- Treatment of lymphoma in the elderly: an update. (1997) (5)
- Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy (2021) (4)
- The assessment of chemotherapy risk in elderly cancer patients: Validation of the CRASH score in an Italian cohort. (2015) (4)
- Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma. (2016) (4)
- Comprehensive geriatric assessment in elderly cancer patients. Preliminary results from the Italian Group of Geriatric Oncology - GIOGer (1999) (4)
- Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma (2022) (4)
- Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review (2019) (4)
- DPYD and UGT 1 A 1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (2018) (4)
- The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation (2022) (4)
- Ethics in Oncology: Principles and Responsibilities Declared in the Italian Ragusa Statement (2016) (4)
- Eslicarbazepine in patients with brain tumor-related epilepsy: a single-center experience (2020) (4)
- Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (2021) (4)
- Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters (2021) (4)
- 1222 How much does performance status correlate with multidimensional geriatric assessment in elderly patients with cancer (EPC) (1995) (4)
- Prediction of Bene fi t from Checkpoint Inhibitors in Mismatch Repair De fi cient Metastatic Colorectal Cancer: Role of Tumor In fi ltrating Lymphocytes (2020) (4)
- A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study (2021) (4)
- Phase II Study of Teniposide (VM26) in Cutaneous T‐Cell Lymphomas (1990) (4)
- Persistent Generalized Lymphadenopathy Syndrome vs «Aids» - Unrelated Malignant Lymphoma: Comparison of Presenting Clinical and Laboratory Findings in 88 Patients (1989) (4)
- Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study (2022) (4)
- “Care and self-care” “god as a mirror of the self” (2009) (4)
- Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma (2011) (4)
- Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients (2022) (4)
- UEG Week 2016 Poster Presentations (2016) (4)
- Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib (2019) (4)
- Impact of Gastrointestinal Side Effects on Patients’ Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study (2021) (4)
- 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab) (2015) (4)
- Clinico-pathological and molecular characterization of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal? (2018) (4)
- Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. (2013) (4)
- Urine 2-Hydroxyglutarate in Glioma (2016) (4)
- Non Hodgkin's Lymphomas in 137 patients aged 70 years or older: a retrospective EORTC Lymphoma Group Study (1988) (4)
- Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy (2022) (3)
- Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020–Sep 2020; Sep 2020–May 2021) in the Veneto Oncology Network: The ROVID study (2022) (3)
- Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group. (2017) (3)
- 515PFOLFOXIRI PLUS BEVACIZUMAB (BV) OR PLUS ANTI-EGFR ANTIBODIES IN RAS AND BRAF WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS): ANALYSIS OF TUMOR RESPONSE. (2014) (3)
- Is burnout affecting life satisfaction in oncologists? The moderating role of family concerns in an Italian sample (2020) (3)
- Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The CARACAS study. (2020) (3)
- Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study (2017) (3)
- O-008Phase II study of tivantinib (ARQ 197) in combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC) (2015) (3)
- Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). (2015) (3)
- Comprehensive geriatric assessment (CGA) for outcome prediction in elderly patients (PTS) with glioblastoma (GBM): A mono-institutional experience. (2018) (3)
- Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial. (2014) (3)
- Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer? (2018) (3)
- O-011Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO (2016) (3)
- The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. (2018) (3)
- Two-drug gemcitabine-based first-line treatment of elderly patients (pts) with small cell lung cancer (SCLC): The G-STEP program. (2006) (3)
- Clinical and laboratory findings at presentation in persistent generalized lymphadenopathy vs malignant lymphoma. (1988) (3)
- The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience (2014) (3)
- LBA23FOLFOX4/XELOX in stage II–III colon cancer: Efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial (2017) (3)
- Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients (PTS) with mismatch repair deficiency (MMRd): An observational study. (2019) (3)
- Patients with metastatic castration-resistant prostate cancer (mCRPC) who are long-term responders (LTR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA. (2017) (3)
- Multiple myeloma. (1998) (3)
- Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology (2018) (3)
- Re: Chronically depressed mood and cancer risk in older persons. (1999) (3)
- Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with IDH-mutated glioma. (2014) (3)
- LBA16REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients (2017) (3)
- To Transplant or Not to Transplant During the SARS‐CoV‐2 Pandemic? That Is the Question (2020) (3)
- Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS). (2018) (3)
- Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the “BRAF, BeCool” platform. (2018) (3)
- mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs. (2021) (3)
- Practical Importance of Routine Paraffin-Embedded Bone Marrow Biopsy in Multiple Myeloma (1987) (3)
- Treatment of multiple myeloma and acute myelogenous leukemia in the elderly: an update. (1997) (2)
- Simultaneous care in oncology: Assessment of benefit in relation to symptoms, sex, and age in 753 patients (2022) (2)
- 478OEfficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S) (2017) (2)
- An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer (2022) (2)
- Phase II study of esorubicin (4′ -deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma (2004) (2)
- Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial (2016) (2)
- High dose chemotherapy followed by autologous hematopoietic stem cell transplantation for advanced germ cell tumors: state of the art and a single-center experience. (2021) (2)
- Immune-checkpoint inhibitors in brain metastases from renal cell carcinoma: a battle was lost but not the war. (2019) (2)
- Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience (2022) (2)
- 507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer (2020) (2)
- Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. (2023) (2)
- A multicentre phase 2 study of carboplatin (C) plus pegylated liposomal doxorubicin (PLD) as first-line chemotherapy for patients (pts) with advanced or recurrent endometrial carcinoma (AEC): The END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer) Group. (2006) (2)
- Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care (2022) (2)
- Nab-paclitaxel (Nab-P) and gemcitabine (G) first-line chemotherapy (CT) in patients (pts) with metastatic pancreatic cancer (mPC) who relapsed after adjuvant treatment (ADJ T): A “REAL LIFE” study. (2017) (2)
- 539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study (2020) (2)
- Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients** (2017) (2)
- Gliomatosis cerebri: a monocentric real-life experience (2021) (2)
- Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network during the first and second pandemic waves. (2021) (2)
- Hodgkin's disease in patients 70 years of age or more. A retrospective EORTC Lymphoma Group Study. (1990) (2)
- Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview (2022) (2)
- Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study. (2019) (2)
- D26Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer: the HERACLES B TRIAL (2016) (2)
- Second medical opinion in oncological setting. (2021) (2)
- MEDICAL RADIATION THERAPIES (2013) (2)
- Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials. (2018) (2)
- 999P Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma (2020) (2)
- Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas (2021) (2)
- Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases (2018) (2)
- Oral Anticancer Therapy Project: Clinical utility of a specific home care nursing program. (2016) (2)
- Phase II study of panitumumab (P) in combination with FOLFOXIRI as first-line treatment of metastatic colorectal cancer (mCRC): Activity in molecularly selected patients (pts). (2012) (2)
- Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center (2022) (2)
- Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 patients. (2017) (2)
- Development of a cure model for the estimation of long-term outcomes in patients with microsatellite instability(MSI)-high metastatic colorectal cancer (mCRC) receiving immune-checkpoint inhibitors (ICIs). (2021) (1)
- Aromatase Inhibitors as Neoadjuvant Treatment in Elderly Patients with Locally Advanced Breast Cancer (2012) (1)
- 96 Comorbidities and concomitant medications at time of diagnosis of prostate cancer: Data from the PROS-IT CNR study (2016) (1)
- 359P Regorafenib in recurrent glioblastoma patients: A large real-life experience (2021) (1)
- Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): Outcomes and safety from a multicenter Italian experience. (2018) (1)
- Commission of the European Communities “Europe Against Cancer” Programme. European school of oncology advisory report. Cancer treatment in the elderly.: 25 (1994) (1)
- Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study (2022) (1)
- Activity, efficacy, and safety of nab-paclitaxel (Nab-P) and gemcitabine (G) in heaviliy pretreated advanced pancreatic cancer (APDAC) patients (pts): A multicenter retrospective analysis. (2014) (1)
- Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of Oncology (2022) (1)
- Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC). (2017) (1)
- A liquid biopsy-based approach identifies myeloid cells, STAT3 and arginase-1 as predictors of glioma risk score and patients' survival (2021) (1)
- Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients. (2019) (1)
- 721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study (2020) (1)
- Validation of a cancer-specific Oncological-Multidimensional Prognostic Index (Onco-MPI) for mortality prediction in older cancer patients. (2013) (1)
- Suspicious for recurrent low and high grade glioma and indeterminate MRI: the role of 18F-DOPA PET/CT. (2017) (1)
- PD-0005PHASE II STUDY OF SINGLE AGENT CETUXIMAB IN KRAS G13D MUTANT METASTATIC COLORECTAL CANCER (MCRC) (2014) (1)
- Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study. (2015) (1)
- Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): An observational study (2019) (1)
- Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review (2022) (1)
- O-0010LONG-SURVIVORS WITH LUNG METASTASES AND KRAS MUTATIONS HAVE AN INCREASED RISK TO DEVELOP BRAIN METASTASES FROM COLORECTAL CANCER (2013) (1)
- Antigen rapid diagnostic test monitoring for SARS‐CoV‐2 in asymptomatic and fully vaccinated cancer patients: Is it cost‐effective? (2022) (1)
- Hodgkin's disease cell lines Expression of functional CD40 antigen on Reed-Sternberg cells and (2011) (1)
- 713PACTIVITY, EFFICACY AND SAFETY OF NAB-PACLITAXEL (NAB-P) AND GEMCITABINE (G) IN ADVANCED PANCREATIC CANCER (APDAC) ELDERLY PATIENTS. (2014) (1)
- Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma (2022) (1)
- 399P Role of geriatric assessment and oncological multidimensional prognostic index in elderly patients with metastatic colorectal cancer in a real-world setting (2022) (1)
- A Pilot Study Correlating IDH-1/2 Gene Status with 2-Hydroxyglutarate (2HG) Concentration in Plasma and Urine from Patients (PTS) with Glioma (2012) (1)
- 4019 POSTER Aromatase Inhibitors as Neoadjuvant Treatment in Elderly Patients (>70 Years) With Locally Advanced Breast Cancer: a Monoinstitutional Experience (2011) (1)
- Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer (2004) (1)
- OC-0146: The PROS-IT CNR study: comorbidities and medications at the time of diagnosis of prostate cancer (2016) (1)
- Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2 (2020) (1)
- Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis (2020) (1)
- Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis (2021) (1)
- Evolution of the clinical approach to the elderly patient with cancer (1999) (1)
- Are circulating tumor cells (CTCs) a feasible tool for predicting disease recurrence and survival in nonmetastatic (M0) colorectal cancer (CRC) (2015) (1)
- QUALITY OF LIFE AT TIME OF DIAGNOSIS OF PROSTATE CANCER: PRELIMINARY RESULTS OF THE PROS-IT CNR STUDY (2017) (1)
- P-0221 Folfoxiri Plus Bevacizumab as First-Line Treatment of Braf Mutant Metastatic Colorectal Cancer Patients (2012) (1)
- 933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study (2021) (1)
- P18.05.A Bevacizumab in atypical and anaplastic meningiomas: the BEMEN study (2022) (1)
- 1517P Role of geriatric assessment and oncological multidimensional prognostic index (onco-MPI) in older patients (age ≥70 years) with advanced soft tissue sarcoma in a real-world setting (2022) (1)
- Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer. (2018) (1)
- Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. (2012) (1)
- S26MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role (2016) (1)
- E04Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study (2015) (1)
- CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer (2019) (1)
- Active protection from chemotherapy toxicity. (1998) (1)
- Teniposide is not effective in chronic lymphocytic leukemia (2004) (1)
- 297P The genetic profile of primary and recurrent gliomas: A mono-institutional experience using next-generation sequencing (2022) (1)
- A large, multicenter, retrospective study to identify a cutoff of MGMT methylation status by quantitative pyrosequencing approach in patients (PTS) with glioblastoma (GBM). (2018) (1)
- Factors predicting time-to-progression (TTP) and overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC) treated by combination gemcitabine (G) and pegylated liposomal doxorubicin (PLD) chemotherapy. (2010) (1)
- Prognostic and predictive role of comprehensive geriatric assessment (CGA) in elderly patients with metastatic renal cell cancer (RCC) treated with sunitinib (SUN) or pazopanib (PAZ): A single center experience. (2019) (1)
- Abstract 1342: Polymorphisms in genes involved in mitophagy pathway predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE3 phase III trials (2019) (1)
- Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study (2019) (1)
- Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification. (2022) (1)
- Association of VEGFA SNP rs2010963 with prognosis and prediction of vascular toxicity of bevacizumab in recurrent glioblastomas. (2013) (1)
- ACTR-78. TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA (2017) (1)
- 2334 Nab Paclitaxel (Nab-P) and Gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) patients (pts): An Italian “real life” study (2015) (1)
- Erratum to "Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life" [Eur J Cancer 69 (2016) 110-118]. (2017) (1)
- Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study (2021) (1)
- Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy (2020) (1)
- Multidimensional geriatric evaluation in elderly with cancer (Meeting abstract). (1997) (1)
- Vindesine (VDS) in Padua and Milan (1981) (1)
- High frequency of cross-lineage antigenic expression in acute myeloid leukaemia cells of elderly patients. (1989) (1)
- Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey (2023) (1)
- Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial (2022) (1)
- Bone metastases from neuroendocrine tumors: clinical and biological considerations (2022) (1)
- BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts). (2014) (1)
- Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis. (2015) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer (2018) (1)
- P08.65 Evaluation of Clinical Benefit in patients treated with Bevacizumab (2016) (0)
- 166. 5-Aza-2′-deoxycytidine (decitabine) is an effective agent for differentiation therapy of advanced myelodysplastic syndromes (MDS) (1992) (0)
- The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer. (2016) (0)
- Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma. (2014) (0)
- FDG-PET/CT imaging in gynecologic cancers: Is there an advance on patient management? (2011) (0)
- Adjuvant chemotherapy in American and Italian patients with BRCA1/2-associated breast cancer. (2011) (0)
- Trabectedin and Radiation Therapy for Cardiac Metastasis From Leiomyosarcoma: A Case Report and Review of the Literature (2022) (0)
- The prognostic value of thyroid hormone levels in immunotherapy-treated patients with metastatic urothelial carcinoma (2023) (0)
- 1273P Early integration between oncologic treatment and palliative care: Experience of the simultaneous care outpatient clinic at Veneto Institute of Oncology, ESMO Designated Center (2022) (0)
- First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiAlLdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis. (2016) (0)
- PPA_A_351771 353..362 (2022) (0)
- Contents Vol. 60, 2014 (2015) (0)
- The waiting list for prostate cancer treatment in italy: Analysis from the Pros-IT CNR survey (2019) (0)
- Next-generation sequencing (NGS) for identifying actionable molecular alterations in patients with newly diagnosed and recurrent IDHwt-glioblastoma (GBM): A large mono-institutional experience. (2022) (0)
- Prophylaxis with Intrathecal Chemotherapy and High Dose Methotrexate in Patients with Diffuse Large B Cell Lymphoma at High Risk for Central Nervous System Relapse: A Single Centre Experience (2018) (0)
- Emerging New Drugs for the Treatment of Human Lymphomas (2000) (0)
- 360P Metronomic temozolomide therapy in heavily pretreated patients with recurrent glioblastoma: A large mono-institutional retrospective study (2021) (0)
- Role of the oncological-multidimensional prognostic index in older patients with metastatic colorectal cancer treated in a real-world setting. (2019) (0)
- F28Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc) (2015) (0)
- Chemotherapy for Pelvic Bone Tumors (2021) (0)
- 2900 Predictors of survival in glioblastoma patients treated with fotemustine at first relapse after Stupp regimen: Analysis of GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology) (2015) (0)
- 165. Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia (AML) patients by site-selective 8-chloro-cyclic adenosine 3′, 5′ monophasphate (8-CI-cAMP): a new approach for differentiation therapy of AML in humans (1992) (0)
- Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer. (2019) (0)
- 1023: IMMUNOREACT 6: YOUNG PATIENTS WITH RECTAL CANCER HAVE A LOWER INFILTRATION OF CD4+ T CELLS WITHIN THE HEALTY RECTAL MUCOSA BUT NO MISMATCH REPAIR GENES DEFECTS. (2022) (0)
- Guidelines for radiation therapy of lung cancer in the elderly (1999) (0)
- Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (2020) (0)
- Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study. (2019) (0)
- PP7. Economic evaluation of patients (pts) with lymphomas enrolled into phase II–III clinical trials (ct) in an oncology centre (1997) (0)
- Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial. (2018) (0)
- OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma patients (2018) (0)
- Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy (2020) (0)
- 425PTHE ROLE OF TEMOZOLOMIDE AND RADIATION THERAPY IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A MONOINSTITUTIONAL RETROSPECTIVE STUDY. (2014) (0)
- 778: IMMUNOREACT 5: FEMALE PATIENTS WITH RECTAL CANCER HAVE A HIGHER EXPRESSION OF PDL-1 AND A HIGHER INFILTRATION OF T-CELLS WITHIN THE RECTAL MUCOSA. (2022) (0)
- S29Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies - THE CORNUCOPIA STUDY (2016) (0)
- Angiogenesis inhibitor bevacizumab and symptomatic anal ulcers in metastatic colorectal cancer patients: A single center experience. (2017) (0)
- O-019Distant-relapse analysis of STAR-01, a randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer (2016) (0)
- The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. (2020) (0)
- The MaiSON Project (Italy). Developing Integration Strategies for Oncology Organizations/Associations through a Participatory Approach (2013) (0)
- An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A). (2021) (0)
- 310P Bevacizumab in meningiomas: A monocentric experience (2022) (0)
- P17.06.B Different dosage of bevacizumab treatment in recurrent IDHwt glioblastoma/IDHmut grade 4 astrocytoma and its impact on outcome (2022) (0)
- COLORIMETRIC DETECTION OF AMPLIFIED BCR/ABL SEQUENCES : A SURVEY PERFORMEDON ARCHIVAL SLIDES (1996) (0)
- Multi-institutional prostate cancer unit of Padova: Review of activity and performance indicators of the first 18 months after ISO9001 certification. (2023) (0)
- The MaiSON Project (Italy). Developing integration strategies for oncology organizations/associations through a participatory approach. (2013) (0)
- P02.02.A Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: a large mono institutional experience (2022) (0)
- A novel MGMT methylation-based prognostic score in patients with glioblastoma. (2017) (0)
- MON-P075: Awareness and Consideration of Malnutrition Among Oncologists: Insights from an Exploratory Survey (2016) (0)
- 369MO Final results of depatuxizumab mafodotin plus temozolomide in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO) (2020) (0)
- BIOM-21. THE SIGNIFICANCE OF TERT PROMOTER MUTATIONS, TELOMERE LENGTH AND MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED AND RECURRENT IDH-WILDTYPE GLIOBLASTOMA (GBM): A LARGE MONO-INSTITUTIONAL STUDY (2021) (0)
- 1524 Multidisciplinary simultaneous care service of Istituto Oncologico Veneto (IOV) ESMO-DC: An eperience of early integration between oncologic treatment and palliative care (2015) (0)
- Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera statement (2022) (0)
- TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients. (2016) (0)
- Management and Outcomes of Older Patients (Age ≥ 70 Years) with Advanced Soft Tissue Sarcoma and Role of Geriatric Assessment and Oncological Multidimensional Prognostic Index (Onco-MPI) in a Real-World Setting (2023) (0)
- 3035 Distress Thermometer (DT) in multidisciplinary management of cancer patients (pts): quality of life and quality of care (2009) (0)
- Predictive factors of bevacizumab efficacy in relapsed glioblastoma patients. (2014) (0)
- P01.040 Identification of a predictive biomarker of response to regorafenib in relapsed glioblastoma patients (2018) (0)
- Use of nivolumab (N) and cabozantinib (C) for treatment of the metastatic renal cell carcinoma (mRCC) in the Veneto region: Results of AMOUR study. (2021) (0)
- Patterns and Outcomes of Treatment in Elderly Patients with Ovarian Cancer: A Retrospective Mono-Istitutional Study (2012) (0)
- Long-term outcome of sunitinib in metastatic renal cell carcinoma: Single center experience. (2013) (0)
- Comprehensive geriatric assessment (CGA) can categorize elderly glioblastoma (GBM) patients into three groups predicting survival: A monoinstitutional study (2019) (0)
- Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9). (2023) (0)
- Feasibility of Genetic Aberrations Analysis in the Circulating Tumor Cells (CTCS) (2012) (0)
- Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial (2022) (0)
- Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib (2019) (0)
- Lymphoma: Clinico-Pathological Findings and Outcome + ALK (2010) (0)
- R02Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study (2015) (0)
- Paternity, relationship, sexual activity and fertility in testicular cancer (TC) survivors (TCS): Results from a single institution observational prospective study. (2021) (0)
- The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients (2018) (0)
- The integration of palliative care into treatment of oncology patients at the Istituto Oncologico Veneto (IOV): The interdisciplinary clinic of simultaneous care. (2016) (0)
- P.20.6 THE UNIQUE PROFILE OF ANTERIOR GRADIENT 2 (AGR2) IN BARRETT'S METAPLASIA(S) (2012) (0)
- Abstract P1-05-06: Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA): A guide to the management of advanced breast cancer (ABC) (2017) (0)
- Results of the phase II TRUST trial of induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC). (2016) (0)
- Other than restaging phase: serial FCH-PET/CT scans can predict the reponse to chemotherapy (CT) in castrate-resistant prostate cancer (CRPCa)? (2015) (0)
- Does neutrophil to lymphocyte ratio correlate with toxicities and outcome of patients with genitourinary cancers treated with checkpoint inhibitors? (2019) (0)
- First-line sunitinib in patients with renal cell carcinoma (RCC) and von Hippel-Lindau syndrome (VHL). (2011) (0)
- a detailed clinical, pathological and molecular characterization (2019) (0)
- S31A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and Temozolomide (TMZ) (2016) (0)
- The outstanding evolution of radical prostatectomy in the last seven years in italy: Comparative analysis on more than 1,500 patients from MIRROR-SIU/LUNA vs. Pros-IT-CNR surveys (2019) (0)
- Immunotherapy in RAS mutant mCRC: Could CTLA-4 blockade increase the efficacy of anti PD-1 agents? Preliminary clinical results of the NERDY study. (2023) (0)
- Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study. (2020) (0)
- Multivariable analysis of predictors of side effects of cabazitaxel in the Italian Expanded Access Program. (2015) (0)
- SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study (2022) (0)
- IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients - a cohort study. (2023) (0)
- How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study (2020) (0)
- Systemic Treatments for Grade II and III Meningiomas (WHO) (2021) (0)
- Estimated Direct Costs of Renal Cancer by Stage of Disease at Diagnosis and Phase of Its Management: A Whole-Disease Model. (2023) (0)
- Can serial FCH-PET/CT scans predict the response to treatments in castrate resistant prostate cancer? (2018) (0)
- Metastatic colorectal cancer (mCRC) treatment: A high-volume, single-center, real-life experience. (2016) (0)
- Vindesine overdose. (1982) (0)
- How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study (2020) (0)
- Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14). (2020) (0)
- Abstract CT214: AlfaOmega- a master protocol empowering precision research in colorectal cancer (2019) (0)
- P17.53THE COMBINATION OF CARMUSTINE WAFERS AND FOTEMUSTINE IN RECURRENT GLIOBLASTOMA PATIENTS: OUR EXPERIENCE (2014) (0)
- Abstract PD1-02: Circulating tumor DNA (ctDNA): Areal-timeapplication of precision medicine to the management of metastatic breast cancer (MBC) (2017) (0)
- Do pathological parameters of primary tumor correlate with overall survival (OS) of metastatic clear-cell renal cell carcinoma (ccRCC)? (2016) (0)
- Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study (2016) (0)
- P09.28 MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role. (2017) (0)
- North Thames Dialysis Study [4] (multiple letters) (2001) (0)
- A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point? (2019) (0)
- D28The FUNNEL: a precision medicine project for metastatic colorectal cancer (2016) (0)
- 361O Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study (2020) (0)
- 651: An array-based pharmacogenetic study on elderly patients with advanced breast cancer treated with aromatase inhibitors (2014) (0)
- S01Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): a metanalysis of randomized clinical trials (RCTs) (2016) (0)
- 2924 Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: An exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study (2015) (0)
- Regorafenib in recurrent glioblastoma patients: A large real-life experience. (2021) (0)
- PL02.5.A The clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in newly diagnosed and recurrent IDHwildtype glioblastoma (GBM) patients (PTS): A large mono-institutional s (2021) (0)
- Retrospective analysis of sorafenib as first- or second-line targeted therapy in patients with mRCC: Three-year Italian experience. (2013) (0)
- Treatment effectiveness in advanced breast cancer patients in Italy: Ten years experience. (2013) (0)
- Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2. (2020) (0)
- 2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study (2015) (0)
- Abstract 4841: GSTM1 and GSTT1 polymorphisms in population-based study of colorectal cancer risk. (2013) (0)
- The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study (2022) (0)
- The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome. (2018) (0)
- P01.118 Prognostic factors and management of gliomatosi cerebri (GC) from real life experience of two neuroncology centers (2018) (0)
- 1604P Aggregated analysis of treatment and survival outcome of all metastatic renal cell carcinoma patients treated from 2014 to 2018 in the Veneto region, Italy (2020) (0)
- 8746 POSTER Could Hypertension Be a Potential Biomarker in Patients With Recurrent Glioblastoma Treated With Antiangiogenic Drugs? -a Retrospective Analysis (2011) (0)
- P17.07.A Metronomic temozolomide therapy in heavily pretreated patients with recurrent glioblastoma: a large mono-institutional retrospective study (2022) (0)
- AVAREG: a phase 2, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma (2016) (0)
- 363P Clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and MGMT promoter methylation status in newly diagnosed and recurrent IDHwildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study (2021) (0)
- A retrospective study analyzing the association between tumor response (TR) according to Mcdonald criteria (MC) on MRI and survival (OS) in patients (PTS) with glioblastoma (GBM) treated with antiangiogenic drugs (AD). (2011) (0)
- Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib (2020) (0)
- Dose-dependent dissociation of effects of 5aza CdR on growth and differentiation of the human leukemic cell line U-937 (1994) (0)
- F22Survival analysis of patients with metastatic renal cell carcinoma treated with sunitinib: a single centre, real-word experience. (2015) (0)
- Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials. (2019) (0)
- Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial. (2020) (0)
- P04.17DIAGNOSTIC VALUE OF PLASMA AND URINARY 2-HYDROXYGLUTARATE TO IDENTIFY PATIENTS WITH IDH-MUTATED GLIOMA (2014) (0)
- D09Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + Bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh) (2016) (0)
- 2921 Low-dose Fotemustine in elderly patients with recurrent glioblastoma: A phase II prospective study (2015) (0)
- Phase II Evaluation of Vindesine in Mycosis Fungoides, Extraosseous Plasmacytoma and other Hematologic Malignancies (1982) (0)
- Spectrophotometric detection of RT-PCR-amplified BCR/ABL fusion transcripts. A survey performed on archival hematologic slides. (1997) (0)
- Mismatch repair deficiency (MMRd) in glioma patients (PTS): Frequency and correlation with clinical, histological and molecular characteristics. (2018) (0)
- Renal cell carcinoma: the population, real world, and cost-of-illness (2022) (0)
- Efficacy of Radiation Treatement in Ocular Adnexa Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Evaluation in a Single Center Experience (2017) (0)
- Abstract LB-232: Derazantinib (ARQ 087) pharmacodynamics: Alterations in FGF19/21/23 and phosphate in patients with cholangiocarcinoma (2018) (0)
- Totally Implantable Venous Access Devices: A Randomized Controlled Trial on the Effect of Psychological Support on Quality of Life and Body Image (BI-PORT) (2021) (0)
- Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients (2019) (0)
- 727PSAFETY AND EFFICACY OF TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) IN UNRESECTABLE BILIARY CANCER. (2014) (0)
- Medication-related osteonecrosis of the jaw in patients with bone metastases from solid tumors: analysis of the Istituto Oncologico Veneto case series (2021) (0)
- Gastrointestinal Cancer (2019) (0)
- previously untreated patients with follicular lymphoma Monitoring of minimal residual disease after CHOP and rituximab in (2013) (0)
- Malignancies of Myeloid and Lymphoid Origin CD30 Ligand Is Frequently Expressed in Human Hematopoietic (2013) (0)
- 468PActivity of temozolomide (TMZ) in patients (PTS) with malignant pheochromocytoma or paraganglioma (MPP): A mono-institutional retrospective study (2017) (0)
- Phase II study of esorubicin (4 ' -deoxydoxorubic in) in locally advanced or metastatic head and neck carc inoma (0)
- occurring as a second tumor: the GIMEMA experience Clinicobiological features and outcome of acute promyelocytic leukemia (2013) (0)
- PO-338 Recurrent glioblastoma: a complex scenario dominated by loss of MMR proteins (2018) (0)
- 718PNAB-PACLITAXEL (NAB-P) AND GEMCITABINE (G) IN PRETREATED ADVANCED PANCREATIC CANCER (APDAC) PATIENTS (PTS): A MULTICENTRE RETROSPECTIVE ANALYSIS. (2014) (0)
- Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9. (2023) (0)
- P09.29 Anaplastic Astrocytoma (AA) and Glioblastoma (GBM): a real-life experience in Padua Neuro-Oncology Center (2017) (0)
- Prognostic value of baseline G8 geriatric assessment in a real-life population of elderly metastatic colorectal cancer patients: The Gold Study. (2022) (0)
- Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study. (0)
- Should bevacizumab (B) be included in the first-line treatment of elderly patients with advanced colorectal cancer (CRC)? Results from a community-based Italian observational study. (2012) (0)
- A real-world application of liquid biopsy (LB) in metastatic colorectal cancer (mCRC). (2020) (0)
- Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study. (2023) (0)
- OS7.3 Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients (2019) (0)
- Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies: The CORNUCOPIA study. (2016) (0)
- CTNI-50. REGORAFENIB IN RECURRENT GLIOBLASTOMA PATIENTS: A LARGE REAL-LIFE EXPERIENCE (2021) (0)
- North Thames Dialysis Study (2001) (0)
- Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab (2019) (0)
- TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group (2017) (0)
- Comprehensive Geriatric Assessment (CGA) and ONCO-Mpi Predict Mortality in Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: A Retrospective Evaluation in a Single Center Experience (2016) (0)
- Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): A metanalysis of randomized clinical trials (RCTs). (2016) (0)
- ANGI-09. BEVACIZUMAB IN ATYPICAL AND ANAPLASTIC MENINGIOMAS: THE BEMEN STUDY (2022) (0)
- Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial. (2017) (0)
- 355P Temozolomide combined with fractionated stereotactic radiotherapy for large brain metastases: A propensity-matched Study (2017) (0)
- Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study (2022) (0)
- Aromatase inhibitors in elderly patients with advanced breast cancer: An exploratory pharmacogenetic study. (2014) (0)
- Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case report. (2020) (0)
- P11.20.A Correlation between thyroid function and regorafenib activity in recurrent IDH wild-type(IDHwt) glioblastoma(GBM) patients: a large monocentric study (2022) (0)
- Worsening of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) can predict radiologic progressive disease (RPD) in glioblastoma (GBM) patients (PTS) treated with radiation therapy (RT) and temozolomide (TMZ): a mono-institutional prospective study. (2017) (0)
- Preliminary results using PET/MR in glioblastoma patients treated with regorafenib: an 18F-FET and DWI-ADC comparison (2021) (0)
- Immunological relevance of the tumor associated antigen (TAA) COA-1 in colorectal cancer (CRC). (2006) (0)
- Rehabilitation Treatment in Older Cancer Patients (2018) (0)
- Elderly patients with glioblastoma: where are we going? (2017) (0)
- 2916 A prospective study analyzing quality of life and cognitive function in patients with glioblastoma treated with RT and Temozolomide: Impact of age and gender (2015) (0)
- An Overview of Intracranial Ependymomas in Adults (2021) (0)
- Partial splenic embolization in chemotherapy-induced thrombocytopenia: A retrospective analysis with long term follow-up. (2017) (0)
- Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair–deficient metastatic colorectal cancer: Immunological and molecular profiling (2022) (0)
- 576PPHARMACOGENETIC PROFILING FOR TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINES. FINAL REPORT FROM AN ANCILLARY PROTOCOL TO THE TOSCA (THREE OR SIX COLON ADJUVANT) TRIAL. (2014) (0)
- Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study. (2017) (0)
- Prognostic and predictive role of CTCs and AR-V7+ CTCs expression in metastatic catrate resistant prostate cancer (mCRPC): A feasibility study. (2018) (0)
- An Exploratory Analysis of AMPK and ACC Activation in Colorectal Primary Tumors and their Corresponding Metastasis (2012) (0)
- Abstract A087: Empowering precision medicine in metastatic colorectal cancer: preliminary results from the FUNNEL platform (2018) (0)
- Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study. (2016) (0)
- Chemotherapy followed by radiotherapy in small cell carcinoma of the lung (SCCL) (1982) (0)
- Chlorozotocin treatment of advanced gastrointestinal cancer. (1983) (0)
- Predictive role of MGMT status in recurrent glioblastoma (GBM) patients (PTS) treated with antiangiogenic drug (AD) plus temozolomide (TMZ) or CPT-11. (2012) (0)
- S23Anaplastic Astrocytoma (AA) and Glioblastoma (GBM): a real-life experience in Padua (2016) (0)
- Endometrial metastatic neoplasia: Prognostic factors. (2011) (0)
- E02Awareness and consideration of malnutrition among italian oncologists: insights from an exploratory survey (2016) (0)
- Sorafenib plus daily low dose temozolomide for relapsed glioblastoma: A phase II study. (2011) (0)
- Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy (2017) (0)
- The clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in newly diagnosed and recurrent IDH-wildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study. (2021) (0)
- The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancer. (2022) (0)
- Chemotherapy (CT) for advanced soft tissue sarcoma (STS) in older patients (pts): Toxicity and outcomes in a single center experience. (2016) (0)
- Anaplastic astrocytoma (AA) and glioblastoma (GBM): a real-life experience in Padua Neuro-Oncology Center (2016) (0)
- A multicentre, prospective phase 2 study of weekly schedule of carboplatin (C) plus paclitaxel (P) in first-line treatment of elderly patients (pts) with ovarian cancer (OC). The MITO (Multicentre Italian Trials in Ovarian cancer)-5 study. (2016) (0)
- NI-26COMPARATIVE ANALYSIS OF THE RANO AND MACDONAD'S CRITERIA IN RECURRENT GLIOBLASTOMA TREATED IN THE RANDOMIZED PHASE II TRIAL AVAREG WITH BEVACIZUMAB OR FOTEMUSTINE. (2014) (0)
- Phase II study with 4-Demethoxydaunorubicin per os in elderly patients affected by non Hodgkin lymphoma and multiple myeloma (1988) (0)
- Simultaneous Care clinic (SCC): A three-year monoinstituional experience. (2017) (0)
- Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma: efficacy, safety and prognostic factors (2021) (0)
- Efficacy of pTACE (DEBIRI) as a neoadjuvant therapy for colorectal liver metastases (2015) (0)
- Prognostic role of Oncological Multidimensional Prognostic Index (Onco-MPI) in elderly patients with urological cancers. (2020) (0)
- Author's Reply to: Patient-centered Medicine in Palliative Cancer Care: The Impossible Choice between Physician's Responsibility and Patient's Preferences (2017) (0)
- R28Pre-emptive pharmacogenetic testing implementation for chemotherapy dosage optimization: the translational experience at CRO of Aviano (2015) (0)
- High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients (2022) (0)
- HER2 expression and extensive molecular characterization of resected brain metastases from colorectal cancer: The HEROES study. (2022) (0)
- Multidisciplinary osteoncologic approach to bone metastases: Analysis of a large, mono-institutional cohort. (2017) (0)
- First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response (2014) (0)
- R13Clinical and molecular predictors of survival in elderly glioblastoma patients treated with radiotherapy and concomitant temozolomide: a multicenter study of aino (Italian Association of Neuro-Oncology) (2015) (0)
- CTNI-15. REGORAFENIB IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED, IDH WILDTYPE GLIOBLASTOMA: A PHASE I DOSE-FINDING STUDY (REGOMA-2) (2022) (0)
- PD-0765 Bowel bother and function after RT for prostate cancer : the prospective QoL Pros-IT CNR study (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Vittorina Zagonel?
Vittorina Zagonel is affiliated with the following schools:
